Welcome to our dedicated page for InflaRx N.V. SEC filings (Ticker: IFRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InflaRx N.V. filings document foreign-private-issuer reporting for a Nasdaq-listed biopharmaceutical company focused on complement-targeted anti-inflammatory therapeutics. Form 6-K reports furnish interim financial statements, management discussion and analysis, press releases on izicopan and vilobelimab programs, Nasdaq compliance notices, annual general meeting materials and shareholder voting results.
The company’s regulatory records also describe capital-structure matters, including ordinary-share offerings under an effective Form F-3 shelf registration statement and incorporation by reference into Form S-8 registration statements. Governance disclosures cover Dutch statutory annual accounts, audit instructions, director reappointments, board authorization matters and related shareholder approvals.
InflaRx N.V. shareholder Commodore Capital LP, together with Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, reports beneficial ownership of 7,475,000 ordinary shares of InflaRx N.V. as of August 10, 2026. This represents 5.1% of the outstanding ordinary shares, based on 147,368,221 shares outstanding as of June 30, 2026.
The filers report no sole voting or dispositive power over InflaRx shares and shared voting and shared dispositive power over 7,475,000 shares. Commodore Capital LP acts as investment manager to Commodore Capital Master LP, while Atkinson and Kramarz are managing partners exercising investment discretion.
InflaRx N.V. received an updated Schedule 13G/A from Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen reporting significant ownership of the company’s common shares, nominal value (euro)0.12 per share. Montanova Capital and Aaron Cowen each report beneficial ownership of 22,933,910 common shares, representing 15.6% of the class, with shared voting and dispositive power over these shares and no sole power. Averill Master Fund, Ltd. reports beneficial ownership of 18,460,710 common shares, representing 12.5% of the class, also with shared voting and dispositive power only. All securities reported are directly owned by advisory clients of Montanova Capital, and, other than Averill Master Fund, no advisory client is stated to beneficially own more than 5% of the common shares. The reporting persons each disclaim beneficial ownership except to the extent of their pecuniary interest.
InflaRx N.V. is registering and may offer and sell, from time to time, ordinary shares with an aggregate offering price of up to $65,000,000 through Leerink Partners LLC in an at-the-market offering under an existing Form F-3 shelf. Sales may be made on Nasdaq or other permitted methods, with Leerink receiving up to 3.0% of gross proceeds as commission. Assuming sales at $2.01 per share, up to 32,338,308 ordinary shares would be outstanding after the offering, compared with 147,368,221 shares outstanding as of June 30, 2026. As of that date, net tangible book value was $165.6 million, or $1.12 per share; on a pro forma basis after a full $65 million sale it would be $228.5 million, or $1.27 per share, implying purchaser dilution of $0.74 per share at the assumed price. InflaRx reports under IFRS, focuses on anti-C5a/C5aR inflammatory therapies, and plans to use any net proceeds primarily for research and development of its clinical and preclinical programs, as well as working capital and general corporate purposes.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of InflaRx N.V. ordinary shares. They collectively report 8,911,348 Ordinary Shares, representing 6.1% of the class, based on 147,292,859 Ordinary Shares outstanding as cited from a May 7, 2026 prospectus.
The Reporting Persons have shared voting and dispositive power over all 8,911,348 shares and no sole voting or dispositive power. The shares are held by investment funds managed by Sirenia, and SILV Fund, Ltd. has the right to receive dividends or sale proceeds for more than 5% of the outstanding Ordinary Shares. Sirenia and Mr. Silverstein have entered into a Joint Filing Agreement to file this ownership report together.
InflaRx N.V. is the issuer of Ordinary Shares with a nominal value of 0.12 EUR per share, CUSIP N44821101. A group of investment entities and individuals associated with Farallon Capital Management, L.L.C. report aggregate beneficial ownership of 3,325,000 Shares, representing 2.3% of InflaRx’s outstanding Ordinary Shares as of June 30, 2026.
Farallon Capital Management, as investment manager to several investment partnerships referred to as the Farallon Funds, has shared voting and shared dispositive power over these Shares. The Farallon Funds themselves are entitled to receive dividends and sale proceeds from the Shares beneficially owned on their behalf.
FMR LLC and Abigail P. Johnson report a significant ownership position in Inflarx N.V. common stock. FMR LLC is shown as beneficially owning 8,163,341 shares of common stock, representing 5.5% of the class, with sole dispositive power over all of these shares and no shared voting or dispositive power. Abigail P. Johnson is reported as beneficially owning the same 8,163,341 shares, also representing 5.5% of the class, with sole dispositive power and no voting power. The filing notes that one or more other persons have rights to receive dividends or proceeds from these securities, but no other individual person has an interest exceeding five percent of the outstanding common stock.
InflaRx N.V., a Netherlands-incorporated biopharmaceutical company focused on anti-C5a/C5aR inflammatory therapies, has filed a Form F-3 shelf registration to offer, from time to time, up to $250,000,000 of ordinary shares, debt securities, warrants, purchase contracts and units. Specific terms, pricing and timing will be set in future prospectus supplements.
The company’s ordinary shares trade on Nasdaq under the symbol IFRX. On August 5, 2026, the last reported sale price was $1.77 per share. As of June 30, 2026, ordinary shares held by non‑affiliates had an aggregate market value of $269,050,484, based on 120,111,823 shares at $2.24 per share. As of June 30, 2026, issued share capital was €17,684,186.52, divided into 147,368,221 ordinary shares.
InflaRx’s lead oral small‑molecule C5aR1 inhibitor, izicopan, is being advanced in ANCA‑associated vasculitis and additional renal diseases, with Phase 2 planning underway and open‑label studies planned in aHUS, IgA nephropathy and C3 glomerulopathy. The intravenous anti‑C5a antibody vilobelimab has Emergency Use Authorization from the FDA and a European marketing authorization under exceptional circumstances for critically ill, invasively mechanically ventilated COVID‑19 patients. Proceeds from any offerings are intended for general corporate purposes and other business opportunities.
InflaRx N.V. reported a net loss of €16.2 million (loss €0.17 per share) for the six months ended June 30, 2026, compared with €22.7 million (loss €0.35 per share) a year earlier. No revenue was recorded after discontinuing U.S. GOHIBIC sales, but the operating loss narrowed as expenses declined.
Research and development spending fell to €8.9 million from €14.2 million, general and administrative expenses to €5.7 million from €8.3 million, and sales and marketing to €0.1 million from €2.5 million, largely reflecting the commercial wind-down. Other income from grants was €0.5 million versus €1.5 million, while net financial result moved to a €2.0 million loss, driven mainly by a €7.1 million negative revaluation of pre-funded warrants partly offset by foreign-exchange gains.
A May 2026 underwritten offering of 75 million ordinary shares at $2.00 per share generated net proceeds of €119.3 million, lifting cash to €146.6 million and total funds (including marketable securities) to €158.4 million at June 30. Management states this should fund planned operations into the end of 2029, yet also discloses that events and conditions create a material uncertainty that may cast significant doubt on the Group’s ability to continue as a going concern. Development is being focused on the oral C5aR inhibitor izicopan in ANCA-associated vasculitis and complement-mediated renal diseases, while reassessing vilobelimab’s role in AAV following EU actions on comparator avacopan.
InflaRx N.V. is reassessing its ANCA-associated vasculitis (AAV) strategy in Europe after the EMA’s Committee for Medicinal Products for Human Use recommended revoking Tavneos’ marketing authorization in the EU. The company plans to engage EMA on two C5a/C5aR-targeting programs, vilobelimab and the oral inhibitor izicopan.
Izicopan’s Phase 2 planning in AAV continues across multiple regions, and InflaRx views vilobelimab as Phase 3-ready in AAV after two completed Phase 2 trials in the U.S. and Europe. Partner Staidson is running a Phase 3 AAV trial in China with BDB-001, a vilobelimab cell line-derived antibody.
Vilobelimab is also approved in the EU as GOHIBIC under exceptional circumstances for SARS-CoV-2-induced ARDS and has U.S. Emergency Use Authorization for certain ventilated COVID-19 patients. Prior studies showed a 23.9% relative reduction in 28‑day all‑cause mortality versus placebo, supporting its role in severe inflammatory settings.